A Study of Tirzepatide (LY3298176) on the Reduction of Morbidity and Mortality in Adults With Obesity (SURMOUNT- MMO)
- Conditions
- Obesity, OverweightTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Registration Number
- CTIS2022-501744-15-00
- Lead Sponsor
- Eli Lilly & Co.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 15000
Be overweight or have obesity, Are over age 40 and have cardiovascular disease at least 3 months before study start, Women at least 55 years of age without established heart disease but have cardiovascular risk factors, such as smoke tobacco, abnormal levels of fats (lipids) in the blood, high blood pressure, or kidney disease., Men at least 50 years of age without established heart disease but have cardiovascular risk factors, such as smoke tobacco, abnormal levels of fats (lipids) in the blood, high blood pressure, or kidney disease.
Have type 1 diabetes or type 2 diabetes at the beginning of the study, Have any of the cardiovascular conditions such as: heart attack, stroke, procedure to treat coronary artery disease, or heart failure requiring IV medication or left ventricular assist device within 3 months before the start of the study
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method